Medacta Group SA (MEDGF) Q2 2026 Sales/Trading Call Transcript

SA Transcripts 161.42K Followers Follow Medacta Group SA ( MEDGF ) Q2 2026 Sales/Trading Call July 31, 2026 9:00 AM EDT Company Participants Francesco Siccardi - Chief Executive Officer Conference Call Participants Michelle Büchler - Zürcher Kantonalbank, Research Division Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Graham Doyle - UBS Investment Bank, Research Division Presentation Operator Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Medacta First Half 2026 Preliminary Unaudited Revenue. [Operator Instructions] At this time, I would like to turn the conference over to Mr. Francesco Siccardi, CEO of Medacta. Please go ahead, sir. Francesco Siccardi Chief Executive Officer Thank you very much, and good morning or good afternoon to everybody. Welcome to Medacta H1 2026 Preliminary Unaudited Revenue Conference Call. The slides of today's presentation can be found on the Medacta Investor Relations website along with the media release. And I would like to remind all participants that the presentation includes forward-looking statements, which are subject to risks and uncertainties. Listeners and readers are therefore encouraged to refer to the disclaimer on Slide #2 of today's presentation. And after the housekeeping remarks, I will now turn to Slide #4 and start with the highlights of today's presentation. So Medacta did continue to outperform the market in H1 2026 with a constant currency growth rate of almost 10%, 9.7% in constant currency, reaching EUR 368 million. We did announce as well 2 major expansion projects, which are the following. The first one is the completion of our expansion shell or manufacturing unit shell in Ticino in Rankata, while the second news is about a land that we purchased 2 days ago to be precise, in Tennessee, and that's where we're going to develop our new manufacturing capacity in the U.S. The performance of H1 allows